GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:000606621 | Liver | HCC | alcohol metabolic process | 208/7958 | 353/18723 | 2.80e-10 | 9.50e-09 | 208 |
GO:00082022 | Liver | HCC | steroid metabolic process | 188/7958 | 319/18723 | 1.96e-09 | 5.63e-08 | 188 |
GO:00066942 | Liver | HCC | steroid biosynthetic process | 104/7958 | 173/18723 | 2.13e-06 | 2.91e-05 | 104 |
GO:000672011 | Liver | HCC | isoprenoid metabolic process | 65/7958 | 116/18723 | 2.23e-03 | 1.11e-02 | 65 |
GO:003430812 | Liver | HCC | primary alcohol metabolic process | 55/7958 | 102/18723 | 1.30e-02 | 4.67e-02 | 55 |
GO:00060667 | Oral cavity | OSCC | alcohol metabolic process | 179/7305 | 353/18723 | 4.54e-06 | 5.21e-05 | 179 |
GO:00066945 | Oral cavity | OSCC | steroid biosynthetic process | 89/7305 | 173/18723 | 5.77e-04 | 3.30e-03 | 89 |
GO:00067203 | Oral cavity | OSCC | isoprenoid metabolic process | 59/7305 | 116/18723 | 6.18e-03 | 2.33e-02 | 59 |
GO:00082024 | Oral cavity | OSCC | steroid metabolic process | 146/7305 | 319/18723 | 7.78e-03 | 2.85e-02 | 146 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
AKR1B15 | SNV | Missense_Mutation | | c.485G>T | p.Gly162Val | p.G162V | C9JRZ8 | protein_coding | deleterious(0.01) | benign(0.099) | TCGA-AG-A01W-01 | Colorectum | rectum adenocarcinoma | Female | >=65 | I/II | Chemotherapy | 5-fluorouracil | CR |
AKR1B15 | SNV | Missense_Mutation | | c.716G>T | p.Ser239Ile | p.S239I | C9JRZ8 | protein_coding | deleterious(0) | probably_damaging(0.991) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
AKR1B15 | SNV | Missense_Mutation | novel | c.622N>A | p.Pro208Thr | p.P208T | C9JRZ8 | protein_coding | deleterious(0) | probably_damaging(0.976) | TCGA-AP-A1DK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
AKR1B15 | SNV | Missense_Mutation | rs373511828 | c.205N>T | p.Arg69Cys | p.R69C | C9JRZ8 | protein_coding | tolerated(0.06) | benign(0.1) | TCGA-AP-A1DV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
AKR1B15 | SNV | Missense_Mutation | | c.875C>A | p.Ser292Tyr | p.S292Y | C9JRZ8 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-B5-A11E-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
AKR1B15 | SNV | Missense_Mutation | novel | c.215A>G | p.Asp72Gly | p.D72G | C9JRZ8 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-B5-A3FC-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
AKR1B15 | SNV | Missense_Mutation | | c.604C>T | p.Pro202Ser | p.P202S | C9JRZ8 | protein_coding | deleterious(0.01) | probably_damaging(0.923) | TCGA-BG-A186-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
AKR1B15 | SNV | Missense_Mutation | | c.324N>T | p.Trp108Cys | p.W108C | C9JRZ8 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-DI-A1BU-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Chemotherapy | paclitaxel | SD |
AKR1B15 | SNV | Missense_Mutation | novel | c.626N>C | p.Val209Ala | p.V209A | C9JRZ8 | protein_coding | tolerated(0.56) | benign(0.233) | TCGA-DI-A1BU-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Chemotherapy | paclitaxel | SD |
AKR1B15 | SNV | Missense_Mutation | novel | c.133N>A | p.Leu45Ile | p.L45I | C9JRZ8 | protein_coding | tolerated(0.09) | benign(0.006) | TCGA-E6-A1LX-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |